



EXPRESS MAIL NO. EV336651664US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Charles Q. Huang et al.
Application No. : 10/648,843
Filed : August 26, 2003
For : CRF ANTAGONISTIC QUINO- AND QUINAZOLINES
Art Unit : 3857
Docket No. : 690068.587C1
Date : February 24, 2004

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the 9 references set forth on the attached Form PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/266,662, filed October 8, 2002, now U.S. Patent 6,610,678, which is a divisional of prior Application No. 09/403,393, filed October 19, 1999, now U.S. Patent 6,482,836. The references listed on the attached Form PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the

examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC




Karl R. Hermanns
Registration No. 33,507

Enclosures:
Form PTO-1449

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

C:\690068.587C1\428988_1.DOC

FORM PTO-1449
(REV.7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
690068.587C1APPLICATION NO.
10/648,843INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

APPLICANTS

Charles Q. Huang et al.

FILING DATE

August 26, 2003

GROUP ART UNIT

3857

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
		WO 95/33750	12/14/95	WIPO		
		WO 96/35689	11/14/96	WIPO		
		WO 98/08846	03/05/98	WIPO		
		WO 98/29397	07/09/98	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

		Michne, W. et al., "Novel Inhibitors of Potassium Ion Channels on Human T. Lymphocytes," <i>J. Med. Chem.</i> 38:187-1883, May 1995.
		Olls, D. et al., "Heterocyclic Mesomeric Bataines," <i>J. Chem. Soc. Perkin Trans.</i> , pp. 953-956, 1989.
		Schroeder et al., "Non-Steroidal Anti-Inflammatory Agents IV ---," <i>Eur. J. Med. Chem.-Chim. Ter.</i> 14/6:499-506, 1979.
		Sen, A. et al., "Synthesis of New Antimalarials," <i>J. Indian Chem. Soc.</i> 36:80-807, 1959; also cited as Chem. Abstract #54:50478-1960.
		Womack, J. et al., "Potential Antimalarias," <i>J. Med. Chem.</i> 12(12):1218-1220, 1971.

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).